Growth Metrics

Eton Pharmaceuticals (ETON) Common Equity (2019 - 2025)

Historic Common Equity for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $23.1 million.

  • Eton Pharmaceuticals' Common Equity rose 4470.93% to $23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.1 million, marking a year-over-year increase of 4470.93%. This contributed to the annual value of $24.4 million for FY2024, which is 5783.42% up from last year.
  • As of Q3 2025, Eton Pharmaceuticals' Common Equity stood at $23.1 million, which was up 4470.93% from $24.0 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Common Equity registered a high of $24.4 million during Q1 2025, and its lowest value of $11.2 million during Q3 2022.
  • Over the past 5 years, Eton Pharmaceuticals' median Common Equity value was $16.0 million (recorded in 2024), while the average stood at $17.2 million.
  • In the last 5 years, Eton Pharmaceuticals' Common Equity surged by 102824.21% in 2021 and then crashed by 3791.23% in 2022.
  • Quarter analysis of 5 years shows Eton Pharmaceuticals' Common Equity stood at $17.6 million in 2021, then decreased by 25.82% to $13.1 million in 2022, then rose by 18.34% to $15.5 million in 2023, then surged by 57.83% to $24.4 million in 2024, then fell by 5.33% to $23.1 million in 2025.
  • Its last three reported values are $23.1 million in Q3 2025, $24.0 million for Q2 2025, and $24.4 million during Q1 2025.